Last reviewed · How we verify

NCT07066267

Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)

Recruiting now NA Last updated 17 July 2025
What this trial tests

NA trial testing Experimental in Female Infertility in 20 participants. Currently enrolling.

Timeline
25 April 2025
Primary endpoint
31 December 2025
31 December 2026

Quick facts

Lead sponsorSunkaky Medical Cooperation
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment20
Start date25 April 2025
Primary completion31 December 2025
Estimated completion31 December 2026
Sites1 location across Sri Lanka

Drugs / interventions tested

Conditions studied

Sponsor

Sunkaky Medical Cooperation

Who can join

Adults 29 to 39, female only, with Female Infertility or Oocyte Competence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the potential of autologous adipose stem cell (ASC) mitochondrial transfer (ASCENT) to oocytes along with intracytoplasmic sperm injection (ICSI)as a means of enhancing embryo development and improving the success rate of in patients with a history of multiple IVF failures. Embryo quality plays a crucial role in determining the success of assisted reproductive technologies and directly contributes to repeated pregnancy failures. Several factors, including age, physiological conditions, genetics, and environmental influences, can significantly impact embryo quality. Oocytes, the largest cells in the human body, are heavily reliant on mitochondria. Mitochondria's role in providing energy for oocytes is crucial, and insufficient energy production has been linked to poor oocyte and embryo quality. Some human studies have shown that increasing oocyte mitochondrial mass can improve embryo quality in patients who have experienced repeated IVF failures.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Mitochondrial DAMPs as a critical driver in the development of acute graft versus host disease and emerging mitochondria targeted therapeutic strategies.
    Raguraman V, Prabhu YD, Velmurugan GV, Hildebrandt GC, et al · · 2025 · cited 1× · PMID 41607789 · DOI 10.3389/fimmu.2025.1740433

Verify or expand the search:

Other trials of Experimental

Trials testing the same drug.

Other recruiting trials for Female Infertility

Currently open trials in the same condition.

Other Sunkaky Medical Cooperation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07066267.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing